These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 20160184)

  • 1. Antiplatelet therapy after percutaneous coronary intervention: Should another regimen be "TAPT?".
    Croce K
    Circ Cardiovasc Interv; 2010 Feb; 3(1):3-5. PubMed ID: 20160184
    [No Abstract]   [Full Text] [Related]  

  • 2. Omeprazole: a possible new candidate influencing the antiplatelet effect of clopidogrel.
    Gurbel PA; Lau WC; Tantry US
    J Am Coll Cardiol; 2008 Jan; 51(3):261-3. PubMed ID: 18206733
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention.
    Harmsze AM; van Werkum JW; Souverein PC; Breet NJ; Bouman HJ; Hackeng CM; Ruven HJ; ten Berg JM; Klungel OH; de Boer A; Deneer VH
    J Thromb Haemost; 2011 Oct; 9(10):1892-901. PubMed ID: 21854540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standard- vs high-dose clopidogrel after percutaneous coronary intervention.
    Jeong YH; Park Y; Kim IS
    JAMA; 2011 Jun; 305(24):2520; author reply 2521-2. PubMed ID: 21693737
    [No Abstract]   [Full Text] [Related]  

  • 5. Clopidogrel, genetics, and drug responsiveness.
    Freedman JE; Hylek EM
    N Engl J Med; 2009 Jan; 360(4):411-3. PubMed ID: 19164193
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetic determinants of response to clopidogrel and cardiovascular events.
    Simon T; Verstuyft C; Mary-Krause M; Quteineh L; Drouet E; Méneveau N; Steg PG; Ferrières J; Danchin N; Becquemont L;
    N Engl J Med; 2009 Jan; 360(4):363-75. PubMed ID: 19106083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Collet JP; Hulot JS; Pena A; Villard E; Esteve JB; Silvain J; Payot L; Brugier D; Cayla G; Beygui F; Bensimon G; Funck-Brentano C; Montalescot G
    Lancet; 2009 Jan; 373(9660):309-17. PubMed ID: 19108880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bedside evaluation of thienopyridine antiplatelet therapy.
    Price MJ
    Circulation; 2009 May; 119(19):2625-32. PubMed ID: 19451364
    [No Abstract]   [Full Text] [Related]  

  • 9. Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans.
    Lee JM; Park S; Shin DJ; Choi D; Shim CY; Ko YG; Kim JS; Shin ES; Chang CW; Lee JE; Jang Y
    Am J Cardiol; 2009 Jul; 104(1):46-51. PubMed ID: 19576320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A current problem for regulators. Clopidogrel and pharmacokinetics].
    Zündorf I; Dingermann T
    Pharm Unserer Zeit; 2009; 38(4):360-7. PubMed ID: 19572363
    [No Abstract]   [Full Text] [Related]  

  • 11. Optimizing platelet inhibition in clopidogrel poor metabolizers: therapeutic options and practical considerations.
    Angiolillo DJ; Ueno M
    JACC Cardiovasc Interv; 2011 Apr; 4(4):411-4. PubMed ID: 21511220
    [No Abstract]   [Full Text] [Related]  

  • 12. Concomitant use of clopidogrel and proton pump inhibitors or cimetidine after acute myocardial infarction would increase the risk of re-infarction.
    Sheng-Wen Wang S; Tsai SS; Hsu PC; Yang CY; Wu DC
    Am J Gastroenterol; 2009 Dec; 104(12):3116-7. PubMed ID: 19956146
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinically relevant interaction between clopidogrel and proton pump inhibitors].
    Alban S; Dingermann T; Griese N; Kämmerer W; Schubert-Zsilavecz M; Schulz M; Trenk D; Zagermann-Muncke P
    Pharm Unserer Zeit; 2009; 38(4):370-1. PubMed ID: 19572357
    [No Abstract]   [Full Text] [Related]  

  • 14. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.
    Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Buonamici P; Antoniucci D; Abbate R; Gensini GF
    Am J Cardiol; 2009 Mar; 103(6):806-11. PubMed ID: 19268736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with clopidogrel nonresponsiveness.
    Momary KM; Dorsch MP
    Future Cardiol; 2010 Mar; 6(2):195-210. PubMed ID: 20230261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
    Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton pump inhibitors and clopidogrel.
    Gaglia MA; Waksman R
    Cardiovasc Ther; 2010 Jun; 28(3):169-76. PubMed ID: 20345494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial.
    Kereiakes DJ
    Rev Cardiovasc Med; 2009; 10(2):72-82. PubMed ID: 19593319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPI interactions with clopidogrel revisited.
    Med Lett Drugs Ther; 2009 Feb; 51(1306):13-4. PubMed ID: 19229161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2C19 genotype and proton pump inhibitors in clopidogrel-treated patients: does it take two to tango?
    O'Donoghue ML
    Circulation; 2011 Feb; 123(5):468-70. PubMed ID: 21262991
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.